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Objectives: Tuberculosis (TB) is the leading infectious disease in the developing
world. Delayed-type hypersensitivity skin test diagnoses TB using tuberculin
purified protein derivative (PPD), but this test is incapable of distinguishing
Mycobacterium tuberculosis (MTB) infection from bacillus CalmetteeGue´rin
(BCG) vaccination or an infection caused by nontuberculous mycobacteria (NTM).
This study was performed to evaluate the use of recombinant early secretory
antigenic target 6 (rESAT-6), a secretory protein found only in MTB, Mycobac-
terium bovis, and few other mycobacterial species, as a skin marker for MTB in
guinea pigs.
Methods: We prepared recombinant MTB ESAT-6 and evaluated its use as a
specific antigen for MTB in guinea pigs.
Results: Our results show that the purified MTB rESAT-6 antigen is capable of
inducing a positive reaction only in guinea pigs sensitized to MTB. No such re-
action was observed in the animals sensitized to M. bovis, BCG vaccination, or
NTM (Mycobacterium avium).
Conclusion: Our study results confirm that the ESAT-6 antigen is more specific to
MTB infection than PPD and could be used in more specific skin tests for
detection of MTB in large animals and in humans.1. Introduction
In 2012, estimates indicated 8.6 million new TB
cases and 1.3 million TB-related deaths, of which there
were 1 million human immunodeficiency virus (HIV)-
negative patients, with the remaining 0.3 million beingted under the terms of the
) which permits unrestrict
operly cited.
ase Control and PreventionHIV-positive patients. These data indicate that TB is one
of the important health problems [1]. Furthermore, a
pandemic of tuberculosis (TB) is influenced by increases
in the HIV/acquired immunodeficiency syndrome cases
and emergence of multidrug-resistant and extensively
drug-resistant strains, all of which aggravate theCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
Figure 1. Evaluation of recombinant early secretory anti-
genic target 6 (rESAT-6) gene as polymerase chain reaction
product. Lanes 4 and 5 Z rESAT-6 gene.
ESAT-6 recombinant protein as skin marker 35problem. Therefore, there is a necessity to identify
strategies for controlling TB infection [2].
TB-controlling strategies are based on accurate
diagnosis, but this is not possible with the classical
common technique that is used to screen patients for TB
[3]. Tuberculin purified protein derivative (PPD) test is a
delayed-type hypersensitivity reaction that is widely
used for screening patients with exposure to Mycobac-
terium tuberculosis (MTB) for several decades [4]. PPD
is a mixture of large number of MTB antigens that are
present in nontuberculous mycobacteria (NTM) and
Mycobacterium bovis bacillus CalmetteeGue´rin (BCG)
[5]. Therefore, the PPD skin test can produce a false-
positive reaction in patients who have received the
BCG vaccination or have had exposure to NTM [5]. The
early secretory antigenic target 6 (ESAT-6) gene is
located in the RD1 region and is present in the patho-
genic strains of Mycobacterium such as MTB, M. bovis,
Mycobacterium africanum, Mycobacterium kansasii,
Mycobacterium marinum, Mycobacterium szulgai,
Mycobacterium flavescens; however, this gene is absent
in all strains of M. bovis BCG and in a large number of
NTM [6]. The gene activates one of the most important
virulence factors in MTB and is responsible for inducing
secretion of interleukin-8 (neutrophils) and T-lympho-
cyte chemotactic cytokine [7,8]. In recent years, this
gene was evaluated as a diagnostic tool for detection of
MTB infection in enzyme-linked ImmunoSpot assay
technique and as a candidate for vaccination [9]. We
have successfully cloned and expressed ESAT-6 protein
and evaluated its sensitivity and specificity as a skin test
antigen and compared recombinant ESAT-6 (rESAT-6)
skin test reaction with locally prepared PPD in guinea
pigs.Figure 2. Electrophoresis of recombinant plasmid after
digestion by restriction endonucleases.2. Materials and methods
2.1. Bacterial strains and product
MTB H37Rv genome, Mycobacterium avium, and M.
bovis BCG were obtained from the Tuberculosis
Research Laboratory of Razi Vaccine and Serum
Research Institute (Karaj, Iran). The vector pQE60 was
obtained from the Iranian Recombinant Gene Bank
(Institut Pasteur, Tehran, Iran). PPD produced from
MTB (50 IU/mL) was obtained from Razi Vaccine and
Serum Research Institute. Escherichia coli strains M15
and XL1-blue were grown in Luria-Bertani liquid
media.
2.2. Cloning, expression, and purification
The ESAT-6 gene from H37Rv strains of MTB was
amplified by polymerase chain reaction (PCR). Forward
and reverse primers have sites for BglII and BamHI.
After digesting PCR products with appropriate enzymes,
the fragments were ran on 1% agarose gel and purified.
The ESAT-6 gene was ligated to the pQE60 vector usingT4 DNA ligase and transformed into E. coli XL1-blue
cells. Restriction enzyme analysis was used to screen
the transformants using EcoRI and HindIII and these
were confirmed by sequencing. The pQE60-E6 was
purified from the culture of recombinant E. coli XL1-
blue and transformed into the competent E. coli M15
cells. The transformants were placed on lysogeny broth
plates containing 50 mg/mL ampicillin and 30 mg/mL
Figure 3. Purification of recombinant early secretory anti-
genic target 6 (rESAT-6) protein as determined by sodium
dodecyl sulfateepolyacrylamide gel electrophoresis.
36 J. Moradi, et alkanamycin. Recombinant histidine (His)-tagged ESAT-
6 (rESAT-6) protein was expressed in these cells and
purified by nickel-nitrilotriacetic acid (Ni-NTA) col-
umn. Purified proteins were ran on sodium dodecyl
sulfate (SDS) page and confirmed by Western blotting
(Figures 1e3).
2.3. Sensitization of guinea pigs and skin test
White guinea pigs (n Z 37; weight, 250e300 g)
were obtained from Razi Vaccine and Serum Research
Institute (Karaj, Iran). First, nine guinea pigs were
sensitized by intradermal administration of 0.5 mL
sensitization solution (100 mg MTB, 50 mL paraffin,
and 50 mg pumice stone) and maintained for 45 days
under specific pathogen-free condition. After the sensi-
tization period, guinea pigs were shaved on the back and
flanks, and then each animal, based on the potency test
table (Table 1), received 0.1 mg of protein randomly.
The diameter of reactions on the skin was measured
24 hours after the injection of the sensitization solution.Table 1. Potency test.
Guinea pigs
(Standard) PPD
1 2
No 1/100 1/500 1/2
830 22 20.5 17
831 18.5 18 15
832 27 24.5 16.
838 26.5 23 17
839 25.5 24.5 17.
840 25.5 24 20
841 25 23.5 20
842 23.5 21 19
843 24 21 19.
Total 217.5 200 161
Mean 24.17 22.23 17.
Total for standard Z 579
ESAT-6 Z early secretory antigenic target 6; PPD Z tuberculin purified proDuring skin testing, 28 guinea pigs were tested; seven
groups were formed, with each group consisting of four
guinea pigs. The first group was the control group,
which was sensitized to 0.1 mL of phosphate-buffered
saline. The second group was sensitized to 0.1 mL of
live M. bovis BCG. The third group was sensitized to
5 mg of M. avium. The fourth, fifth, and six groups were
sensitized to 5 mg of PN, DT, and C strains of MTB,
respectively. Guinea pigs were maintained under spe-
cific pathogen-free condition for 45 days. After the
sensitization period, each guinea pig received six in-
jections of PPD (5e25e125 tuberculin units) and
rESAT-6 (0.1e1e10 mg). Twenty-four to forty-eight
hours after the last injection, both axes of the ery-
thema were measured in millimeters by digital
palpation.3. Results
3.1. Cloning, expression, and analysis of rESAT-6
The ESAT-6 gene from the MTB H37Rv genome was
amplified and cloned in the pQE60 expression vector.
The recombinant ESAT-6 protein successfully
expressed in these cells and three-level usage of elution
buffer in Ni-NTA purification column was carried out. A
single band of rESAT-6 protein (approximately 10 kDa)
was determined by SDS page and confirmed by anti-
ESAT-6 antibody in Western blotting.
3.2. Potency test
In this test, nine guinea pigs sensitized to three strains
of MTB randomly received six injections. The potency
of the injections was measured by statistical analysis.
Our results show that the guinea pig model evaluated in
this study is accurate for detection of rESAT-6.(Test) ESAT-6
3 4 5 6
500 1/100 1/500 1/2500
24 20.8 16
19 18.2 14.5
5 27.5 23.2 14
27.2 23 14.5
5 26.2 24.2 15.5
26.8 24.8 19.5
26.7 24 9.5
24.8 22.1 18
5 24.8 23 18
.5 227 203.3 139.5
94 25.22 22.58 15.5
Total for test Z 569.8
tein derivative.
Table 2. Skin test reaction to rESAT-6 and PPD in sensitized guinea pigs (measured in millimeter).
Groups
Buffer BCG
Mycobacterium tuberculosis strains
D4 PN DT C C, DT, PN
N Z 4 N Z 4 N Z 4 N Z 4 N Z 4 N Z 4 N Z 4
5 TU PPD d 12.67 13.83 16.32 15.96 16.20 16.37
25 TU PPD d 14.67 16.33 21 20.90 21.07 21.5
125 TU PPD d 16.33 18.16 22.90 23 23.2 23.5
0$1 rESAT-6 d d d 14 14.02 13 14.75
1 mg rESAT-6 d d d 18.11 18.5 18.80 18.63
10 mg rESAT-6 d d d 20.90 20.53 20.68 21
BCG Z bacillus CalmetteeGue´rin; PPD Z tuberculin purified protein derivative; rESAT-6 Z recombinant early secretory antigenic target 6;
TU Z tuberculin units.
ESAT-6 recombinant protein as skin marker 373.3. Delayed-type hypersensitivity reaction
The hypersensitivity reaction was measured in seven
groups of guinea pigs and analyzed 48 hours after
receiving the injection. The first group (control) that
received the buffer did not show any reaction to rESAT-
6 and PPD (Table 2). The groups sensitized to MTB
strains showed relative sensitivity to PPD and rESAT-6.
Groups sensitized to BCG vaccine and M. avium D4
strain as an NTM showed reactivity to PPD, but no
reactivity to rESAT-6 (Figure 4).Figure 4. Skin test reaction results: (A) Sensitized to Mycobacte
sensitized to Mycobacterium tuberculosis; and (D) sensitized to p
derivative; rESAT-6 Z recombinant early secretory antigenic targ4. Discussion
TB is considered a major global health problem. It
infects millions of people each year and in terms of
mortality rate, TB is the second leading infectious dis-
ease, after HIV [1,10]. TB-controlling strategies are
based on accurate diagnosis, but this is not possible with
the classical common technique that is used to screen
patients for TB [3]. Delayed-type hypersensitivity skin
reaction test uses tuberculin PPD, and is widely used forrium avium; (B) sensitized to bacillus CalmetteeGue´rin; (C)
hosphate-buffered saline. PPD Z tuberculin purified protein
et 6.
38 J. Moradi, et alscreening patients with TB [4]. PPD contains many
antigens that are common among different species of
Mycobacterium, and thus there is a possibility of cross
reactivity between TB and NTM or BCG vaccination in
animals and humans [6]. This has reduced the specificity
of PPD for the diagnosis of TB, and thus many groups
have studied various methods for accurate diagnosis of
TB with other specific MTB antigens. One of the best
candidates for this purpose is the ESAT-6 antigen,
whose gene loci are located in the RD1 region of MTB,
M. bovis, M. africanum, M. kansasii, M. marinum, M.
szulgai, and Mycobacterium flavescens.
However, this antigen is absent on BCG and in 90%
of NTM [11]. In this study, the ESAT-6 antigen of MTB
was successfully cloned and expressed in a prokaryotic
system and purified with a simple one-step purification
system based on affinity chromatography. Several
studies have been carried out regarding recombinant
expression and purification of MTB ESAT-6 in various
systems [12]. Previous studies have shown that injection
of MTB-specific antigens, such as rESAT-6, have good
potential to stimulate immune response [13e15].
Therefore, ESAT-6 can be an appropriate alternative to
PPD for TB diagnosis [16]. The present study confirmed
the results of previous studies. We found that rESAT-6
could only elicit positive skin reactions in MTB, but not
in M. avium or BCG-sensitized guinea pigs. In addition,
we have shown that the use of rESAT-6 as an antigen in
TB skin test was highly sensitive to infection. The
guinea pigs in the test were sensitive to rESAT-6 and the
size (diameter) of skin reaction was very close to that of
PPD. In summary, the results of this study showed that
the TB-specific skin test based on ESAT-6 antigen had
accurate diagnostic ability. Thus, based on results from
present and previous studies, we strongly suggest the use
of rESAT-6 antigen in skin test in large animals and
human volunteers.Conflicts of interest
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